10x Genomics, Inc. has unveiled its latest innovation, the Xenium Prime 5K Pan-Tissue and Pathways panel, marking a significant advancement in single cell and spatial biology. This new panel boasts enhanced chemistry that significantly increases multiplexing capabilities by an order of magnitude. It promises superior sensitivity per gene, improved specificity, and spatial fidelity, along with integrated multimodal cell segmentation. These features contribute to industry-leading speed and throughput, setting a new standard in the field.
Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics, expressed enthusiasm about customer reception, highlighting the panel's appeal due to its high multiplexing capacity and exceptional performance. He emphasized that the Xenium Prime 5K panel excels across critical metrics such as sensitivity, specificity, and throughput. This launch marks the company's fifth major product introduction this year, reinforcing its commitment to pioneering innovations that empower researchers to achieve groundbreaking discoveries.
Key features of the Xenium Prime 5K assay include its capability to profile 5,000 genes comprehensively across various cell types, states, and signaling pathways in multiple tissue and disease contexts. It promises excellent data quality crucial for unraveling disease mechanisms, understanding therapeutics, and studying cell behavior. The assay integrates advanced multimodal cell segmentation technology to ensure high sensitivity, specificity, and spatial accuracy.
Moreover, 10x Genomics touts industry-leading throughput, enabling researchers to analyze up to 472 mm² of human or mouse tissue in six days or less, facilitating rapid insights. The panel is also customizable with up to 100 additional genes, accommodating various research needs including isoforms, exogenous sequences, and viral elements.
The development of the Xenium Prime 5K panel involved rigorous design using extensive single-cell RNA sequencing data from diverse organs and tissues, along with insights from hundreds of cell types and a comprehensive review of over 750,000 peer-reviewed publications to identify highly cited biomarkers. The assay supports an easy, tissue-agnostic workflow compatible with both fresh frozen and FFPE samples, enhancing its versatility for different experimental setups.
To introduce the Xenium Prime 5K panel, 10x Genomics will host a webinar on June 25, 2024, inviting interested attendees to explore its capabilities firsthand. This launch underscores 10x Genomics' mission to advance biological understanding and improve human health through innovative technologies that redefine research possibilities in oncology, immunology, neuroscience, and beyond.
